Driven by R&D innovation and digital transformation, GYBYS accelerates the development and application of new products and technologies while systematically advancing intelligent upgrades across management, production, and marketing. We have established a sound R&D management system to speed up the development of both innovative and generic drugs. By fostering industry-academia-research collaboration, we have built high-end research platforms to facilitate technology transfer and optimize our core technology and patent layout. Ultimately, these efforts enable us to provide patients with higher-quality and more accessible medical solutions.

n Our Commitments

Ø Establish an open and collaborative ecosystem integrating industry, academia, research, and application.

Ø Fortify the foundation for technological breakthroughs with practicality and high efficiency.

Ø Develop a digital intelligent manufacturing model that is smart and user-friendly.

n Our Actions

Ø Strengthening R&D innovation：Through diversified and multi-tiered innovation models, GYBYS has incubated leading technologies and high-value products. Relying on the integrated R&D management platform, we have accelerated the R&D and application of innovative technologies and products. GYBYS actively advances multiple drug research projects into clinical trials and builds a diversified, multi-level, and all-encompassing talent echelon in the biopharmaceutical field to achieve innovation led by talent. The Management Measures for Technological Innovation Awards revised in 2025 specifies the higher standards for awarding technological innovation encouraging researchers to share corporate development results by technological innovation.

Ø Ethics of Science：GYBYS carries out clinical research work based on strict ethical and moral standards. We have formulated a code of conduct for R&D personnel and set up a clinical trial ethics review team to standardize, supervise and audit the behaviors of R&D personnel and the implementation of relevant laws and regulations. The Company has built a comprehensive process to manage IPR risks and clarified the ethical principles and codes of conduct during scientific research and technological development processes, covering project approval, research implementation to achievement application.

Ø Digital Transformation：We will strengthen digital governance and empowerment, accelerate the digital transformation of industries, and embed digital technologies into decision-making analysis, R&D, supply chain operations, marketing, financial management and other processes. We strive to integrate technologies with our business, and build ourselves an industry leading intelligent enterprise.

Ø Inclusive Healthcare：Collaborating with diverse social sectors, GYBYS conducts health education initiatives targeting children, the elderly, and patients with chronic diseases to enhance residents' health management and prevention awareness. We remain committed to strengthening grassroots healthcare by supporting infrastructure development and participating in health assistance campaigns. Specifically, we extend distinctive Traditional Chinese Medicine (TCM) services to villages and communities, helping to bridge urban-rural medical resource disparities. Through these efforts, we aim to disseminate health concepts and deliver tangible well-being to broader grassroots populations.

n Our Performance

Ø Investment in scientific research 90+.

Ø 160 projects are under R&D, covering medicines, innovative generic chemicals, biosimilars and medical devices, with 10 Class 1 innovative drugs included.

Ø We have obtained 29 approvals, including those for drug clinical trials, chemical API listing, drug registration, and consistency evaluation of generic drugs.

n Our Stories

Chen Li Ji holds special training on intellectual property            Zhong Yi, Qi Xing launched the 2025 World Stroke Day and the 13th

                                                                                                     GYBYS Stroke Prevention Day